JPMorgan raises Teva stock price target to $50 on Weltruza approval
JPMorgan raised its price target on Teva (NYSE:TEVA) to $50, citing Weltruza's approval. The stock is near its 52-week high. JPMorgan expects Weltruza to generate $125M in 2027 sales, ramping to $350M in 2028. Other analysts have also raised price targets, citing Teva's growth prospects and pipeline.
How this was made
The 30-second read
Why it matters
The combined analyst upgrades and regulatory clearance are likely to lift TEVA's share price.
Market read
First report of FDA approval and analyst target hikes creates immediate trading opportunity for TEVA.
What to watch
Potential reimbursement delays or competition from other long‑acting injectables.
Background
The article summarizes JPMorgan's analyst upgrade and cites other banks' target raises after Weltruza's FDA clearance.
Ticker impact
JPMorgan raised its price target on Teva to $50 after FDA approval of the Weltruza injectable.
likely upward pressure as investors price in the new target and sales outlook
The approval removes safety warnings, expands the pipeline and triggers a higher price target, which typically drives buying interest.
Market effects
Boosts sentiment for the broader psychiatric drug sector and generic pharma peers.
Positive for US pharma stocks in the near term.
Limited to markets tracking US pharma earnings and FDA approvals.
Counterpoint
If sales forecasts are overly optimistic, the price could stall despite the upgrade.
Key entities
- analystJPMorgan
Raised TEVA price target to $50.
- productWeltruza
FDA‑approved olanzapine long‑acting injectable.
